PAVmed Inc (PAVM)
NASDAQ:PAVM
Want to see PAVM full AI Analyst Report?
PAVM Stock Chart & Stats
$7.75
$0.11(1.44%)
At close: 4:00 PM EST
$7.75
$0.11(1.44%)
Day’s Range― - ―
52-Week Range$3.85 - $28.44
Previous Close$8
Volume99.04K
Average Volume (3M)377.79K
Market Cap
$36.94M
Enterprise Value$13.24M
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$17.01M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 18, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.69
Shares Outstanding7,159,034
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)0.13
Price to Sales (P/S)62.51
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue155.71
Enterprise Value/Gross Profit-57.30
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$40.50Price Target Upside422.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$490.00K
Bulls Say, Bears Say
Bulls Say
Recapitalization & Simplified Cap TableThe multi-step recapitalization materially reduced legacy convertible liabilities and simplified equity instruments, lowering immediate refinancing pressure. A cleaner cap table and secured note provide greater strategic optionality for funding subsidiaries and M&A, improving medium-term financial flexibility.
Significant Lucid Stake And Recurring Fee IncomePAVmed's sizable Lucid equity position and reported management-fee income create a durable non-operational cash and strategic upside channel. Lucid's federal supply wins and payer engagement support sustained test volume and cash generation that can materially bolster PAVmed's liquidity and diversification over the next several quarters.
Veris Commercial Rollout And Device DevelopmentVeris's EHR integration, active clinical registry and progress toward an implantable monitor represent structural commercialization milestones. Building real-world evidence and a regulated device pathway increases the probability of recurring device revenue and reimbursement access if clinical and regulatory targets are met.
Bears Say
Low Cash And Contingent Financing RelianceWith only $6.5M on hand and material contingent proceeds tied to regulatory and payer milestones, the firm's near-term runway is sensitive to timing and receipt of those triggers. Failure or delay to realize contingencies would likely force dilutive recapitalization or cutbacks, constraining execution across subsidiaries.
Persistent Negative Cash Flow And Operating LossesRecurring negative operating and free cash flow indicate the core business is not self-sustaining. Even with episodic revenue rebounds, deeply negative gross profit and operating losses increase dependence on external capital, raising refinancing and dilution risk while limiting ability to fund organic growth or R&D internally.
Milestone And Reimbursement Timing RiskMaterial parts of the company's funding and commercial ramp hinge on regulatory/payor milestones (LCD, FDA). Delays in coverage or clearance directly postpone revenue recognition and contingent financing, increasing runway uncertainty; combined with rising OpEx, timing shifts can materially impair multi-quarter execution plans.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $3.85 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $36.94M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Aug 18, 2026 which is in 59 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on May 15, 2026. The company reported -$4.42 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$3.72.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.47.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 7,159,034 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$4.42 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went up 1.24%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PAVmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.50 (422.58% Upside)
$40.50 (422.58% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.77%
12-Months-Change
Fundamentals
Return on Equity
-49.65%
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
PAVmed Inc
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
PAVM Company Deck
PAVM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized successful capitalization/recapitalization steps, a cleaned cap table, active commercial progress at Lucid and Veris (EHR integration live, VA orders, positive payer engagement), relaunch of the device portfolio with experienced leadership, and measured technical progress on the implantable monitor. At the same time, liquidity remains constrained ($6.5M cash) and a number of positive outcomes depend on milestone-triggered financings (warrants, FDA clearance, Medicare LCD). GAAP results were volatile due to mark-to-market accounting and preferred dividends materially impacted reported earnings; operating expenses have risen ~23% vs. recent quarterly averages. Overall, positives (strategic restructuring, multiple operational milestones, extended Lucid runway, and product development progress) outweigh the near-term financial and milestone risks, but execution and milestone realization will be critical.View all PAVM earnings summariesPAVM Stock 12 Month Forecast
Average Price Target
$40.50
▲(422.58% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
Co-Diagnostics
―
Tenon Medical, Inc.
―
Heart Test Laboratories, Inc.
―
Ownership Overview
13.42% Insiders
0.30% Mutual Funds
6.78% Other Institutional Investors
79.42% Public Companies and
Individual Investors